Gador is an Argentine pharmaceutical company headquartered in Buenos Aires, Argentina, with a significant presence in the central nervous system (CNS) therapeutics market. The company develops and markets pharmaceutical products for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other CNS conditions.
Founded in 1935, Gador is one of Argentina's oldest and most established pharmaceutical companies. The company has evolved from a local distributor to a fully-integrated pharmaceutical company with manufacturing capabilities, research and development programs, and a regional presence across Latin America.
| Attribute |
Details |
| Headquarters |
Buenos Aires, Argentina |
| Founded |
1935 |
| Focus Areas |
CNS, Cardiovascular, Anti-infectives, Oncology |
| Employees |
~1,500 |
| Revenue |
~$200 million USD |
| Stage |
Commercial stage with R&D |
¶ History and Development
Gador was founded in 1935 as a pharmaceutical import and distribution company. Over the decades, the company has evolved significantly:
1935-1970:
- Established as pharmaceutical distributor
- Expanded product portfolio through partnerships
- Built national distribution network
1970-2000:
- Established local manufacturing capabilities
- Developed generic pharmaceutical portfolio
- Expanded into international markets
2000-Present:
- Built innovative R&D capabilities
- Established neuroscience division
- Developed specialty pharmaceutical focus
Gador has a significant presence in Alzheimer's disease treatment:
Marketed Products:
- Rivastigmine: Cholinesterase inhibitor for mild-to-moderate AD
- Donepezil formulations: Various dosage forms
- Combination therapies: Fixed-dose combinations in development
Development Pipeline:
The company has programs in Parkinson's disease:
Marketed Products:
- Levodopa/Carbidopa formulations: Standard treatments
- Dopamine agonists: Oral and transdermal formulations
- COMT inhibitors: Adjunctive therapy
Development Programs:
- Extended-release formulations
- Novel delivery systems
- Disease-modifying candidates
Gador maintains CNS programs in:
- Epilepsy: Anti-epileptic drug portfolio
- Depression: Antidepressant therapies
- Anxiety: Anxiolytic medications
- Schizophrenia: Antipsychotic treatments
| Program |
Target |
Stage |
Indication |
| GAD-201 |
Cholinesterase |
Approved |
Alzheimer's disease |
| GAD-301 |
Dopamine agonist |
Phase 3 |
Parkinson's disease |
| GAD-401 |
NMDA modulator |
Phase 2 |
Alzheimer's disease |
| GAD-501 |
Neuroprotection |
Discovery |
Parkinson's disease |
Gador operates manufacturing facilities in Buenos Aires:
- Primary manufacturing: Oral solid dosage forms
- API production: Active pharmaceutical ingredient synthesis
- Biotech unit: Biological product manufacturing
- Packaging: Primary and secondary packaging
The company maintains:
- GMP certification: Argentine and international GMP compliance
- Quality control: Comprehensive analytical testing
- Regulatory affairs: Experienced regulatory team
¶ Research and Development
Gador's R&D efforts focus on:
- Generic development: Cost-effective generic alternatives
- Novel formulations: Improved delivery technologies
- New chemical entities: Targeted innovative programs
- Biosimilars: Biological product development
The company collaborates with Argentine research institutions:
University of Buenos Aires:
- Joint research programs
- Student training opportunities
- Technology transfer
National Scientific and Technical Research Council (CONICET):
- Basic research collaboration
- Research funding partnerships
Gador has presence across Latin America:
- Argentina: Primary market, market leader in CNS
- Chile: Established presence
- Peru: Growing operations
- Colombia: Distribution partnerships
- Mexico: Strategic partnerships
The company maintains:
- Export operations: Products shipped to 30+ countries
- Licensing agreements: Out-licensing of proprietary products
- Partnership networks: Distribution and commercial partnerships
Gador operates through multiple business units:
- Innovation: Novel drug development
- Generic Pharmaceuticals: Off-patent products
- Consumer Health: Over-the-counter products
- Biotechnology: Biological products
- Export: International operations
The company's strategic priorities include:
- CNS leadership: Maintain leading position in CNS therapeutics
- Regional expansion: Grow presence across Latin America
- Innovation: Develop novel therapeutic approaches
- Generic growth: Expand generic pharmaceutical portfolio
Gador generates revenue through:
- Product sales: Pharmaceutical product revenues
- Licensing: Out-licensing and royalty income
- Export: International product sales
The company invests in:
- R&D: Research and development programs
- Manufacturing: Production facility upgrades
- Commercial: Sales and marketing expansion
- Competition: Increasing competition from international pharma
- Pricing: Pricing pressure from government regulations
- Generic competition: Generic competition for off-patent products
- ANMAT: Argentine regulatory requirements
- International harmonization: Regulatory alignment
- Pricing regulations: Government price controls
- Innovation: Building innovative R&D capabilities
- Talent: Competition for experienced professionals
- Manufacturing: Investment in modern facilities
Gador is a long-established Argentine pharmaceutical company with a strong presence in CNS therapeutics, particularly for Alzheimer's disease and Parkinson's disease. With manufacturing capabilities, a broad product portfolio, and growing R&D capabilities, Gador represents a significant player in the Latin American pharmaceutical market. The company's focus on neuroscience and regional presence position it to continue serving patients across Argentina and Latin America with important therapeutic options.